FibroBiologics Approves Warrant Issuance; CSO Private Placement Closed

What Happened FibroBiologics, Inc. filed an 8‑K reporting results of a Special Meeting of Stockholders held September 17, 2026, and related disclosures. Shareholders approved, for purposes of Nasdaq Listing Rule 5635(d), the issuance of up to 8,163,266 shares issuable upon exercise of certain outstanding common warrants under a June 25, 2026 Securities Purchase Agreement (SPA) and up to 285,714 shares issuable upon exercise of warrants issued under an Engagement Letter with H.C. Wainwright. The company also announced the closing of a private placement with Hamid Khoja, Ph.D., the company’s Chief Scientific Officer, via a press release dated September 17, 2026, and posted an investor presentation to its website on September 18, 2026.

Key Details

• Special Meeting date: September 17, 2026; record date: July 20, 2026.
• Shares represented at the meeting: 3,431,761 of 8,283,193 entitled to vote (~41.4% turnout).
• Vote on Proposal No. 1 (warrant-related issuance): For 3,153,098; Against 258,217; Abstain 20,446. Total potential shares issuable upon exercise: 8,163,266 + 285,714 = 8,448,980.
• Press release announcing the CSO private placement closing furnished as Exhibit 99.1; investor presentation posted on the company website September 18, 2026.

Why It Matters Approval under Nasdaq Listing Rule 5635(d) clears a procedural hurdle so the company can issue the specified shares upon exercise of existing warrants; that affects potential future dilution for current shareholders because up to 8,448,980 additional common shares could be issued if those warrants are exercised. The disclosed private placement involving the company’s Chief Scientific Officer and the newly posted investor presentation are material investor communications that may provide more detail on financing, insider participation, or corporate plans—investors should review the press release and presentation (Exhibit 99.1 and the company website) for further specifics.